Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis - Takeaways - MDSpire

Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis

  • By

  • Karolina Zarańska

  • Grażyna Kamińska-Winciorek

  • Alexander Jorge Cortez

  • Grażyna Wąsik

  • Maksymilian Gajda

  • May 6, 2026

  • 0 min

Share

  • 1

    Dermatologic immune-related adverse events (d-irAEs) in melanoma patients treated with immune checkpoint inhibitors vary from mild to life-threatening.

  • 2

    Continuous dermatological surveillance is essential during immunotherapy to ensure early detection and management of skin toxicities.

  • 3

    Real-world reporting of mild-to-moderate d-irAEs is significantly underreported, highlighting the need for systematic documentation.

  • 4

    Immune checkpoint inhibitors have become the standard of care for advanced melanoma, significantly improving recurrence-free and overall survival.

  • 5

    The incidence of d-irAEs is notably high, affecting 30-40% of patients on anti-PD-1 therapies, with increased severity in combination treatments.

Original Source(s)

Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis

  • by Karolina Zarańska, Grażyna Kamińska-Winciorek, Alexander Jorge Cortez, Grażyna Wąsik, Maksymilian Gajda

  • May 6, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report